State and federal prosecutors are pursuing a lawsuit against Novartis Pharmaceuticals Corp. for paying kickbacks to BioScrip pharmacy. A story in The Wall Street Journal reports that Novartis incentivized BioScrip to recommend refills of its blood transfusion drug, Exjade.
In order to boost sales of Exjade, Novartis provided referrals and rebates to the specialty pharmacy. BioScrip encouraged refills for patients who may not have needed it in exchange for these kickbacks. Exjade is an ...
continue reading...
A blog entry for the Philadelphia Inquirer notes that vaginal mesh implants, like the kind that recently served as the basis of an $11.1 million jury award in New Jersey, were initially marketed as a safer alternative for women suffering from pelvic organ prolapse.